Edition:
United Kingdom

Kamada Ltd (KMDA.OQ)

KMDA.OQ on NASDAQ Stock Exchange Global Select Market

4.55USD
8 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.55
Open
$4.50
Day's High
$4.55
Day's Low
$4.50
Volume
972
Avg. Vol
21,169
52-wk High
$8.55
52-wk Low
$3.75

Latest Key Developments (Source: Significant Developments)

Kamada announces new supply agreement with international organization for KamRAB
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Kamada Ltd :Kamada announces new supply agreement with international organization for KamRAB for post-exposure prophylaxis against rabies infection.Kamada Ltd - the ‍three-year supply agreement will extend through 2020, and is expected to generate revenues for Kamada of approximately $13 million​.  Full Article

Kamada and ‍Chiesi Farmaceutici terminate European distribution agreement for inhaled alpha-1 antitrypsin therapy
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Kamada Ltd ::Kamada Ltd - Co, ‍chiesi Farmaceutici S.P.A. mutually agree to terminate European distribution agreement for inhaled alpha-1 antitrypsin therapy.Kamada Ltd - ‍Kamada now maintains full, worldwide commercial rights to its inhaled aat​.Kamada - ‍ no financial implications related to termination of agreement for inhaled alpha-1 antitrypsin therapy.  Full Article

Kamada and Kedrion seek FDA approval of human rabies immunoglobulin
Thursday, 1 Sep 2016 

Kamada Ltd : Kamada and Kedrion seek FDA approval of human rabies immunoglobulin as a post-exposure treatment .Companies planning for decision from FDA in mid-2017.  Full Article

Kamada meets primary endpoint of U.S. Phase 2 study of inhaled Alpha-1 Antitrypsin
Tuesday, 30 Aug 2016 

Kamada Ltd : Kamada meets primary endpoint of U.S. Phase 2 study of inhaled Alpha-1 Antitrypsin for the treatment of Alpha-1 Antitrypsin deficiency . There were no differences seen in safety parameters between placebo and treatment groups .To utilize results to design U.S. study and support responses to EMA regarding Co's marketing authorization application for inhaled AAT.  Full Article

Kamada reports Q2 adjusted loss per share $0.11
Tuesday, 2 Aug 2016 

Kamada Ltd : Kamada reports financial results for the second quarter and first six months of 2016 . Q2 loss per share $0.04 . Sees FY 2017 sales $100 million . Q2 revenue $19.1 million versus $19.2 million .Sees FY 2016 revenue $75 million to $80 million.  Full Article

Shire and Kamada announce FDA approval of an expanded label for GLASSIA
Wednesday, 15 Jun 2016 

Shire PLC : Shire and Kamada announce FDA approval of expanded label for self-infusion of GLASSIA for the treatment of emphysema due to severe AAT deficiency . Serious adverse reaction observed during clinical trials was exacerbation of chronic obstructive pulmonary disease .Infusion of GLASSIA for the treatment of emphysema due to severe AAT deficiency.  Full Article

Kamada Ltd reports positive interim data in phase 1/2
Wednesday, 6 Jan 2016 

Kamada Ltd:Reports further positive interim data from phase 1/2 study of its alpha-1 antitrypsin to treat graft versus host disease.Says interim results showed that plasma aat levels increased in both cohorts and remained stable for the duration of treatment.Says treatment responses were evaluated as "peak" response and at day 28.Eight of the twelve subjects showed an overall response to treatment, four of which were complete responses and four were partial responses.  Full Article

Kamada Ltd's human rabies immune globulin clears phase 2/3 clinical trial
Wednesday, 23 Dec 2015 

Kamada Ltd:Kamada's human rabies immune globulin successfully meets primary endpoint in U.S. pivotal phase 2/3 clinical trial as a post-exposure treatment.Says expects to file a biologics license application (bla) with the U.S. food and drug administration (FDA) in mid-2016.Says results showed that kamada's igg was safe and well tolerated with no drug-related serious adverse events (saes) experienced.Says plans to file a bla with the FDA in mid-2016.  Full Article

BRIEF-Kamada announces new supply agreement with international organization for KamRAB

* Kamada announces new supply agreement with international organization for KamRAB for post-exposure prophylaxis against rabies infection